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Background: The early management of orthopaedic outpatients by physiotherapists may be useful in reducing
public hospital waiting lists. Physiotherapists in Australia are prevented by legislation and funding models from
investigating, prescribing, injecting and referring autonomously. This gap in service is particularly noticeable in the
management of shoulder pain in early-access physiotherapy services, as patients needing corticosteroid injection
face delays or transfer to other services for this procedure. This trial will investigate the clinical (decision making
and outcomes) and economic feasibility of a physiotherapist prescribing and delivering corticosteroid and local
anaesthetic injections for shoulder pain in an Australian public hospital setting.
Methods/Design: A double-blinded (patient and assessor) non-inferiority randomised controlled trial will compare
an orthopaedic surgeon and a physiotherapist prescribing and delivering corticosteroid injections to the shoulder.
Agreement in decision making between the two clinicians will be investigated, and economic information will be
obtained for estimating disease burden and an economic evaluation. The surgeon and the physiotherapist will
independently assess patients, and 64 eligible participants will be randomised to receive subacromial injection of
corticosteroid and local anaesthetic from either the surgeon or the physiotherapist. Post-injection, all participants
will receive physiotherapy. The primary outcome measure will be the Shoulder Pain and Disability Index measured
at baseline, and at 6 and 12 weeks post-injection. Analysis will be conducted on an intention-to-treat basis
and compared to a per-protocol analysis. A cost-utility analysis will be undertaken from the perspective of the
health funder.
Discussion: Findings will assist policy makers and services in improving access for orthopaedic patients.
Trial registration: Australia and New Zealand Clinical Trials Registry: 12612000532808 First registered: 21 May 2012.
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Patients referred to Australian public health orthopaedic
services face lengthy waiting periods. Publicly accessible
information on outpatient waiting times is scant and
inconsistent. The Australian National Outpatient Care
Database does not report waiting times [1]. Queensland
Health hospital performance data indicate that 54% of
non-urgent outpatient referrals (not specifically ortho-
paedics) will take over a year to be seen [2], and data
from some hospitals reveal that the waiting time to see
orthopaedic specialists may extend beyond 3 years [3].
Furthermore, demands on orthopaedic services and sub-
sequent waiting times are expected to worsen as the
population ages [4] and rates of obesity and arthritis
increase [5].
To combat future escalating delays for patients to ac-
cess services such as orthopaedics, it has been proposed
that the future health workforce should include greater
role substitution and skill transference across professions
[6]. The early management of orthopaedic referrals by
physiotherapists is one example. Physiotherapists have
demonstrated high levels of agreement with orthopaedic
surgeons in the diagnosis and management of ortho-
paedic conditions of the hip, knee [7], and shoulder [8].
Orthopaedic models of care involving extended scope
physiotherapy practice have also reported reduced costs,
reduced waiting times and improved health outcomes;
however, the quality of this evidence to date is generally
low [9]. Corticosteroid injection by specially trained
physiotherapists has been formally available in the UK
since 2000 with a good safety record [10]. Contemporary
UK laws and service delivery models permit appro-
priately trained physiotherapists autonomy in areas of
prescribing, injecting, investigation and referral. In con-
trast, physiotherapists in Australia are prevented by le-
gislation from prescribing and administering medicines.
They are also hindered in requesting radiologist injec-
tion or referring to other specialties by Medicare funding
rules, which require that the request be made by a
doctor. While early physiotherapist assessment of ortho-
paedic patients has been implemented in some Australian
hospitals, patients in need of specific pharmaceuticals or
invasive procedures such as injection are typically re-
turned to waiting lists because their needs are beyond the
scope of Australian physiotherapists. This presents a ser-
vice gap in comparison to UK models of care, particularly
with regards to some orthopaedic conditions such as sub-
acromial impingement syndrome of the shoulder.
Shoulder pain is a common problem, with a popu-
lation prevalence of 20 to 33% [11], annual prevalence
of 2.4% and an annual general practitioner (GP) care-
seeking incidence of 1.5% [12]. Subacromial impinge-
ment syndrome encompasses multifactorial pathology
and is the most frequent cause of shoulder pain [13].Injection of corticosteroid and local anaesthetic to the
subacromial space, sometimes combined with physio-
therapy, is a common management strategy supported
by clinical [14-16] and economic evidence [17-19]. The
management of shoulder pain by Australian GPs is re-
ported to be highly variable, often suboptimal and cha-
racterised by a high reliance upon specialist referral [20].
Yet, despite shoulder pain being one of the most fre-
quent orthopaedic conditions referred to physiothe-
rapists working in early-access orthopaedic services in
Australia [21], these physiotherapists are unable to pro-
vide corticosteroid injection, resulting in delayed care
for these patients. The capacity for injection delivery by
physiotherapists in Australia may provide a solution;
however, little is known of the clinical and economic
outcomes of this model of care.
Existing literature concerning corticosteroid injection
by physiotherapists is sparse and generally low quality.
Positive health outcomes and the absence of adverse
events have been reported; however, data are greatly lim-
ited to observational reports [22-24]. No clinical trials
have yet directly investigated corticosteroid injection by
physiotherapists. Some information pertaining to cor-
ticosteroid injection by physiotherapists may be inferred
from studies into physiotherapist-led orthopaedic mo-
dels of care that have included physiotherapist injection
amongst treatments provided. One unblinded rando-
mised clinical trial utilised superiority statistics and re-
ported that partially supervised physiotherapist care was
not significantly different to that of junior orthopaedic
doctors in terms of health outcomes or patient satisfac-
tion, but hospital costs were lower because physio-
therapists requested fewer X-rays. In this study, some
participants in the physiotherapy group received cortico-
steroid injection but the study did not report the body
region injected, nor whether the physiotherapist actually
delivered the injection [25]. Another unblinded (and
non-randomised) clinical trial compared physiotherapist
management of selected orthopaedic referrals to that of
junior doctors and included physiotherapist corticoster-
oid injection as a treatment option. However, satisfaction
and health outcome measures were not described and,
again, the region of the injection was not reported [26].
Physiotherapists delivered injections in a shoulder treat-
ment trial [27] but the efficacy of the physiotherapist as
the provider of the injection was not investigated.
Therefore, the aim of this trial is to investigate the
clinical and economic feasibility of a physiotherapist
undertaking patient selection, and prescribing and deli-
vering subacromial corticosteroid and local anaesthetic
injection to the shoulder in an Australian public hospital
setting. The primary aim of the study is to compare the
clinical effectiveness of subacromial injection for shoul-
der pain, as delivered by a physiotherapist versus a
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are to assess the agreement between the physiotherapist
and orthopaedic surgeon in patient assessment and se-
lection for injection, to estimate the economic burden of
shoulder pain for patients awaiting orthopaedic care,
and to calculate the costs of physiotherapist versus
orthopaedic surgeon delivery of injections for shoulder
pain. In our opinion, this is a novel and innovative study
in that these research questions have not previously
been investigated in a specific orthopaedic condition
such as shoulder pain, in comparison to a consultant
orthopaedic surgeon, or with a non-inferiority design.
Furthermore, physiotherapist injection has not been pre-
viously reported in an Australian orthopaedic setting.
Methods
Design
A double-blinded (patient and outcome assessor) non-
inferiority randomised controlled trial design will be
used to compare injection decision and delivery by an
orthopaedic surgeon to a model in which the physio-
therapist makes the injection decision and gives the
injection. Clinical decision-making between the two cli-
nicians will also be compared. Economic data will be
obtained for calculation of disease burden and a within-
trial economic evaluation.
Setting, process, inclusion and exclusion criteria
The study will take place at the Gold Coast Hospital and
Health Service, with one upper limb staff specialist
orthopaedic surgeon and one experienced physiothera-
pist who has prior training (in the UK) and experience
in injecting and prescribing. A research assistant will
identify appropriate orthopaedic referrals, contact po-
tential participants, distribute study information, co-
ordinate appointments and gain informed consent from
participants for each part of the research. All partici-
pants will receive verbal and written information about
the risks and benefits of participation and told that they
can change their mind or withdraw at any time. Data
will be stored in locked cabinets and password-protected
digital files. Throughout the trial these will only be ac-
cessible by the research assistant and investigator (LB).
The principal investigator will be given access at trial
completion.
Part One and entry criteria for Part Two
Participants will be included in Part One, the initial as-
sessment phase of the study, if they are aged 18 years
and over, have a new referral from their primary care
doctor to the hospital orthopaedic department for shoul-
der pain and have the ability to read trial literature (in
English) and give consent. Participants will be excluded
if they have prior knowledge of either the researchphysiotherapist or the research orthopaedic surgeon (for
example, from previous interactions or consultation), or
have had no X-ray of the shoulder in the past 12 months.
Written informed consent for Part One will be gained
by the research assistant, following which baseline
demographic and outcome measure data will be col-
lected. The orthopaedic surgeon and physiotherapist,
blind to the other’s assessment and decision, will inde-
pendently examine each participant and their completed
assessment forms will be compared by the research as-
sistant. The order of examination (orthopaedic surgeon
or physiotherapist first) will vary according to clinician
availability. Participants will be unaware of decisions
made by their first assessor while being examined by
their second assessor. In bilateral presentations the side
requested in the GP referral will be addressed. In bilat-
eral referrals both sides will be assessed, the participant
asked to nominate their most troublesome side and
practitioners will make same-day injection decisions for
one side only. Participants will be eligible to enter Part
Two of the study if there is agreement between the
orthopaedic surgeon and physiotherapist on the question
“would you provide subacromial injection today?” In
addition, Part Two participants must be able fill in the
questionnaires and follow post-injection instructions. If
the clinicians disagree about injection or the side to be
injected or both mark “no”, the participant will take no
further part in the research and receive care as directed
by the surgeon. Additional exclusion criteria for entry
into Part Two includes previous surgery to the involved
shoulder, current use of anticoagulant medication, the
need for prophylactic antibiotics with the injection, preg-
nancy or breastfeeding. The flow of participants into
Part One and Part Two of the study are demonstrated in
Figure 1.
Part Two, randomised controlled trial and randomisation
process
Written informed consent for Part Two will be gained
by the research assistant. Participants will then be ran-
domised using concealed allocation to receive an injec-
tion from either the physiotherapist or the orthopaedic
surgeon. The computer-generated randomisation se-
quence will be developed using Excel software by one in-
vestigator (LB) who will conceal the schedule from both
the treating practitioners and the outcome assessor. Par-
ticipants will be given a sealed opaque envelope by the
research assistant, containing a standardised treatment
sheet. This will direct the participant to one of two treat-
ment rooms (Room A or Room B). The professional af-
filiation of the treating practitioner in each room will be
unknown to both the study participants and the out-
come assessor. Following participant randomisation to a
treatment room (that is, a treating practitioner), the
Figure 1 Process of recruitment, consent, randomization,
treatment and measurement.
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procedure before receiving the injection.
Blinding
Throughout Part One the surgeon and the physiotherap-
ist, blind to each other’s findings, will assess participants
independently, in separate rooms. Participants will be
blind to the profession of surgeon and the physiotherap-
ist at all times throughout the entire trial. The outcome
assessor will also be blind to the treating practitioner.
Physiotherapists providing post-injection care will be
asked to not seek information regarding the profession
of the injecting clinician and not discuss the identity or
profession of injecting clinicians with participants. They
will be asked to report any breaches in blinding to the
research assistant. The success of blinding will be as-
sessed immediately post-injection, and at 6 and 12 weeks,
when participants and the outcome assessor will each be
asked to tick whether they think they received their
injection from the physiotherapist or the surgeon. Un-
blinding of a participant will only be permitted in the
event of an adverse event requiring management by the
orthopaedic surgeon.
Interventions
Injection delivered by surgeon or physiotherapist
Participants will receive, from either the physiothe-
rapist or the surgeon, 1 ml betamethasone (CelestoneChronodose; 5.7 mg/ml) mixed with 5 ml 1% lignocaine
hydrochloride, delivered to the subacromial space via an
aseptic injection technique. Methylprednisolone acetate
(1 ml; Depo-medrol; 40 mg/ml) will be used as an alter-
native, and recorded as such, if Celestone is unavailable.
Standard post-injection advice will be given verbally and
through a written information sheet advising reduced ac-
tivity for 1 week, attendance at physiotherapy, as well as
recognition of, and reporting procedures, for any adverse
reactions.
Physiotherapy
All participants who were injected will be referred for
a course of physiotherapy within the hospital’s outpatient
physiotherapy department, beginning approximately
1 week post-injection. The injecting physiotherapist is
not part of this department and will not provide post-
injection treatment. Treating physiotherapists will be
middle to senior outpatient staff with experience in
treating musculoskeletal conditions. The treating physio-
therapists will develop a consensus regarding best prac-
tice exercise and manual therapy interventions used for
shoulder pain. Treatment will be delivered pragmatically
with specific interventions and the number of sessions at
the discretion of the treating physiotherapist. All treating
physiotherapists will be directed to not deliver acupunc-
ture to participants and this will be monitored by the re-
search assistant.
Outcome measures
Outcomes will be measured at baseline, and at 6 and
12 weeks follow-up by the blinded assessor. These time
points were chosen on the basis of a previous study
evaluating subacromial corticosteroid injection that
found greater improvements in the injection group at
6 weeks than at 12 weeks [27]. At baseline the demo-
graphic, service, economic disease burden and clinical
data will be recorded, including age, gender, duration of
condition, imaging findings, dominant arm, affected side,
medicines, occupation, shoulder-related direct and in-
direct costs, and usual service waiting time for care.
Outcome measures and time points are displayed in
Table 1.
Primary outcome measure
The primary outcome measure will be the Shoulder Pain
and Disability Index (SPADI) measured at baseline, and
at 6 and 12 weeks post-injection. The SPADI is a self-
rating tool consisting of 13 questions with a scale of 0 to
10, divided into pain (five questions) and disability (eight
questions) subscales. The two subscales are scored se-
parately; an overall score is then calculated from the
means of the two subscale scores, resulting in a total
score varying from 0 (best) to 100 (worst) [28]. It has
Table 1 Outcome measures and time points
Outcome measure Part of study Time point (weeks)
Part one Part two 0 6 12
Shoulder Pain and Disability Index Yes Yes Yes Yes Yes
Impact and costs questionnaire Yes Yes
Work Productivity and Activity Impairment Questionnaire Yes Yes
Work Limitations Questionnaire Yes Yes
Usual waiting time Yes Yes
Examiner agreement Yes Yes
European Quality of Life, five dimensions, five levels Yes Yes Yes Yes Yes
Pain severity visual analogue scale Yes Yes Yes Yes Yes
Range of movement/pain pre- and post-injection Yes Yes
Adverse events Yes Yes, throughout
Global perceived improvement Yes Yes Yes Yes
Satisfaction visual analogue scale Yes Yes
Post-injection physiotherapy Yes Yes
Labour costs Yes Yes
Medicine use Yes Yes Yes
The table indicates which outcome measures will be used in each part of the trial and when each outcome measure is collected.
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shown to be reliable and valid, including use in patients
with subacromial impingement syndrome of the shoul-
der [28,29].Secondary outcome measures
Economic disease burden at baseline
An impact and costs questionnaire has been developed
to gather shoulder-related direct and indirect costs
including medical care, work earnings, impact and ab-
sence, and also costs of personal assistance required
from others. A 3-month recall period was chosen based
on previously reported patient accuracy in recall over
this period [30,31]. Impact on work productivity will be
further assessed with two work productivity instruments
which are validated in this patient population [32]. The
Work Productivity and Activity Impairment Questionnaire
has been used in many musculoskeletal conditions, is
compatible with economic costing, and is easy to ad-
minister. The Work Limitations Questionnaire [33] is a
widely used presenteeism measure with excellent con-
struct validity and the benefit of being expressed as a
percentage of productivity loss for dual clinical and eco-
nomic analyses.Usual waiting time for care
At the time of initial appointment for assessment, the
usual waiting time to see the orthopaedic surgeon and
the physiotherapist will be obtained from the hospital
waiting list database.Examiner agreement
The two examiners (physiotherapist and orthopaedic
surgeon) will record their assessment, diagnosis, injec-
tion safety and management findings on standardised as-
sessment forms.
Health-related quality of life
The European Quality of Life (five dimensions, five
levels; EQ-5D-5 L) will allow quality of life to be
expressed as utility values varying from 0 to 1, with 1
representing perfect health. This widely used scale builds
upon the earlier EQ-5D-3 L [34] version.
Pain severity
A 100 mm visual analogue scale (VAS) anchored by “no
pain” (0 mm) to worst pain imaginable (100 mm) will be
used to rate participants “worst pain over the last 3 days”.
The VAS has established validity and reliability, with ex-
tensive use in adults [35] and shoulder disorders [36].
Range of movement and pain immediately pre- and
post-injection
Within a period of 20 minutes before and 20 minutes
after injection, the blinded outcome assessor will meas-
ure shoulder range of movement three times in the
scapular plane with a goniometer. The instruction will
be to “take your arm up as far as you feel able”. Follo-
wing the three measurement trials the participant will
then rate on a 100 mm VAS anchored by “no pain”
(0 mm) and worst pain imaginable” (100 mm) the
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these three trials.
Adverse events
Participants will be instructed via the standardised post-
injection information sheet to report any unwanted side-
effects or adverse events to the research team. All ad-
verse events will be recorded. A serious adverse event
will be defined as one that requires hospitalization, re-
sults in persistent incapacity, or requires antibiotic treat-
ment for infection, related to the injection, or anything
worse.
Global perceived improvement
We will use a five-point Global Rating of Change scale,
varying from completely recovered to much worse, to
capture the participants impression of overall change in
their shoulder condition. The Global Rating of Change
has commonly been used for this purpose in painful
shoulder conditions [37].
Satisfaction
Participants will be asked to rate their satisfaction with
care over the 12-week period. A 100 mm VAS anchored
by “not satisfied at all” (0 mm) to “completely satisfied”
(100 mm) will be used.
Post-injection physiotherapy
The number of physiotherapy sessions provided for
post-injection participants will be obtained from hospital
booking systems.
Costs
Labour costs will be obtained from standard health ser-
vice wage scales [38] for the assessing/injecting physio-
therapist, the orthopaedic surgeon, and post-injection
physiotherapy care. Participant medicine use will be re-
corded by the blinded assessor and costs taken from the
Pharmaceutical Benefits Scheme database [39].
Governance
Approvals
Ethical approval (Protocol version 4) and Site Specific
Approval has been obtained through the Gold Coast
Hospital and Health Service Human Research Ethics
Committee, NHMRC code EC00160 (HREC/12/QGC/
30; SSA/12/QGC/97), and Griffith University Human
Research Ethics Committee (MED/23/13/HREC).
The research design requires that the physiotherapist
act beyond the scope of usual professional practice in
Australia and consequently a number of checks and
approvals were required. These included legislative
Approval under Queensland’s Health (Drugs and Poison)
Regulation 1996, credentialing of overseas prescribingand injecting training against equivalent Australian stan-
dards, credentialing under Queensland’s Allied Health
Framework for New/Complex practice, in addition to
local hospital approvals.
Data and adverse event management
Adverse events reported by participants will be brought
to the attention of the orthopaedic surgeon for clinical
management as deemed appropriate. A Data Safety
Monitoring Committee has been established comprising
health service clinicians and experienced university aca-
demics, none of whom are involved in the study. Serious
adverse events will be reported directly to both the Data
Safety Monitoring Committee and the Human Research
Ethics Committee. The biostatistician (SKN) will moni-
tor the progress of the trial through interim statistical
analyses at approximately one- and two-thirds comple-
tion. If the number of interim analyses is not small (for
example, over five), the overall type I error rate could be
controlled by adopting a higher level of significance for
each interim statistical test [40]. Alternatively, a more
formal alpha spending function approach [41] could be
used to allocate some of the pre-specified overall type I
error to each interim analysis. The interim analyses
will be made available in confidence to the Data Safety
Monitoring Committee and the Human Research Ethics
Committee. The Data Safety Monitoring Committee will
have authority to recommend trial cessation to the
Sponsor.
Dissemination
Each participant will be mailed a plain language sum-
mary of the research results. Results will be also dis-
seminated through publication, professional networks,
meetings and conferences.
Sample size
Assuming α = 0.05, β = 0.2, and a standard deviation of
21.7 point change in SPADI scores from baseline, we es-
timate that 54 participants (27 per group) will be re-
quired to test for comparative efficacy between the two
treatments with a non-inferiority margin of 15 points in
SPADI scores. This margin is specified based on clinical
judgment and is approximately two-thirds of the mini-
mum clinically important difference of 23.1 points for
the SPADI at 6 weeks [29]. The standard deviation is ob-
tained by adding 25% to the reported standard deviation
for the change in SPADI scores at 6 weeks from baseline
in a previous study comparing the responsiveness for
SPADI and several indices in patients with shoulder
pain receiving corticosteroid injection [42]. The power
calculation is conservative in the sense that it ignores
the added power inherent in the repeated measures de-
sign (assuming a first-order autoregressive covariance
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0.5, the same sample size will have an increased power
of above 90% using a generalised estimating equation
(GEE) approach [43] for testing the difference in changes
in scores between groups with two repeated follow-up
measurements [44]). However, it is appropriate when
treatment comparisons at the two individual time points
(6 weeks and 12 weeks) are performed to assess the
interaction treatment effect at different time after the
injection. Allowing for a drop-out rate of 15%, we will
recruit a total of 64 participants (32 per group) for injec-
tion. We anticipate this will require us to assess appro-
ximately 256 participants in total, because we estimate
that 25% of participants assessed will be randomised for
injection. This estimate is based on a study in which an
orthopaedic surgeon sent 38% of patients for suba-
cromial injection [8]. We anticipate some practitioner
disagreement will bring the final figure to approximately
25%.
Data analysis
All statistical analyses will be performed on an intention-
to-treat basis with alpha level set at 0.05. As suggested
in an extension of the CONSORT statement for non-
inferiority trial design [45,46], per-protocol analysis will be
conducted and the results obtained by the two approaches
will be compared [47].
Decision making
Agreement between the baseline assessment decisions
from the two clinicians will be investigated using the
proportion of observed agreement, the probability of
chance agreement, the kappa statistics, and the Agree-
ment Coefficient AC1 [48] with the 95% confidence
intervals.
Clinical efficacy
For continuous outcomes, normality of data will be
assessed and parametric tests applied if normality is
upheld. Treatments from the two clinicians will be
compared over time (pre- to post-intervention) on an
intention-to-treat basis using the GEE [43] with a first-
order autoregressive working correlation structure to
account for within-subject correlation for repeated mea-
surements. Robust estimator for covariance matrix will
be adopted. The effects of time (within-group differ-
ences), practitioner (between-group differences), and
practitioner by time interaction (between-group differ-
ences over time) will be included in all models and
assessed using the Wald chi-square test. Non-inferiority
of injection by physiotherapist to injection by surgeon
will be declared if the upper limit of the one-sided confi-
dence interval for the difference in mean change of
SPADI in the physiotherapist group relative to thesurgeon group is smaller than the non-inferiority margin
of 15 points. Model fit and assumptions will be checked
where appropriate within the GEE framework. The GEE
approach works well with missing observations on out-
come measures provided that they are missing com-
pletely at random [49], which will be tested using
likelihood ratio statistics [50]. If the validity of the miss-
ing completely at random assumption was violated, ad-
justment using weighted GEE [51] will be performed.
Appropriate post hoc tests will be conducted if significant
main or interaction effects are identified from the omnibus
analyses [52].
Economic evaluation
A within-trial economic evaluation, adhering to current
guidelines [53], will be undertaken from the perspective of
the health funder. A cost-utility ratio will be constructed
using the formula: cost-utility = (Cost_i – Cost_c) /(QALY_
i – QALY_c), where: QALY = quality-adjusted life years
calculated by mapping the EQ-5D-5 L utility score across
time and calculating the area under the curve, i = inter-
vention group for main effect analysis, and c = control
group. The time horizon for this economic evaluation will
be 12 weeks. Direct costs will include labour costs of the
clinician providing the injection, post-injection phy-
siotherapy and change in medicine usage. Univariate,
multivariate and probabilistic sensitivity analyses will be
conducted to confirm stability of results and adjust for un-
certainty in clinical and economic data.
Discussion
The findings of this study will provide further evidence
informing policy makers, regulators, health professio-
nals, and the public as to the feasibility and safety of
appropriately trained physiotherapists in Australia in
requesting prescribing and administering medicines. The
model of care to be evaluated in this study has the po-
tential to reduce waiting times and improve access to
appropriate and expedited care for patients who pres-
ently face long orthopaedic waiting times for specialist
orthopaedic services. We anticipate this will have sub-
sequent effects in improving patient flow, which could
ultimately benefit both surgical and non-surgical ortho-
paedic pathways. The results may also have application for
the management of other musculoskeletal presentations.
A non-inferiority randomised controlled trial design
was chosen as it is appropriate when comparing an alter-
native treatment with an established proven effective
treatment for a condition, and it is hypothesised that the
alternative will not be superior in efficacy to the estab-
lished treatment. In this case the objective is to determine
whether the alternative treatment (physiotherapist injec-
tion) is not inferior to the existing gold standard (ortho-
paedic surgeon injection). This is done by assessing
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inferiority margin [54].
This study will be limited by its involvement of only one
injecting physiotherapist. This is necessary because there
is presently no regulatory framework, recognised training
curriculum or accreditation process for Australian phy-
siotherapists to prescribe or administer medicines by
injection. The physiotherapist in this study obtained gov-
ernance approvals on the basis of their overseas training
and is not representative of other physiotherapists in
Australia. If physiotherapist-led prescribing and injecting
were to be implemented on a wider scale, appropriate
training and regulatory frameworks would be required.
Further potential limitations of the study include dif-
ferences in practice recency and frequency between the
surgeon and the physiotherapist, as governance ap-
provals permit the physiotherapist to inject only within
the trial. In contrast the surgeon has recent practice and
will have regular ongoing injection practice through
their work outside of the research.
In summary, several knowledge gaps will be addressed
by this research. It will evaluate the safety, feasibility,
and cost of physiotherapists injecting in an Australian
setting. To our knowledge, it will also, for the first time,
compare the decision-making processes and clinical effi-
cacy surrounding injection by a physiotherapist to that
of a consultant orthopaedic surgeon, for a specific ortho-
paedic condition. We believe this to be the first study of
a physiotherapist injecting corticosteroid in Australia,
and it could serve as a benchmark from which subsequent
studies can be conceived to further our understanding of
the potential health benefits of extended-scope acti-
vity within physiotherapy, as well as other allied health
professions.
Trial status
Recruitment began in January 2013, with the first par-
ticipant randomized 16 January 2013.
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